24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
ENZALIEVA 40MG is an Capsules medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | ENZALIEVA 40MG |
|---|---|
| Composition | Enzalutamide Capsules 40mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsules |
| Packaging | Btl (28 cap) |
| Country of Origin | India |
ENZALIEVA 40MG (Enzalutamide Capsules 40mg) is a widely used Capsules medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is a prescription medication containing Enzalutamide 40 mg, a next-generation androgen receptor inhibitor used for the treatment of advanced prostate cancer. It is specifically developed to help control the growth and spread of prostate cancer cells by blocking the effects of male hormones (androgens) that play a crucial role in cancer progression.
Prostate cancer is one of the most commonly diagnosed cancers among men worldwide. While many prostate cancers initially respond to hormone-lowering therapies, some cancers eventually continue to grow despite reduced testosterone levels. ENZALIEVA 40 MG helps address this challenge by directly targeting androgen receptor signaling pathways that cancer cells rely on for survival and multiplication.
Enzalutamide works differently from traditional hormone therapies. Instead of only reducing hormone production, it blocks the androgen receptor at multiple stages, preventing cancer cells from receiving and using hormonal signals. This advanced mechanism helps slow tumor growth, delay disease progression, and support long-term disease management.
ENZALIEVA 40 MG is widely prescribed for patients with:
The medicine has become an important part of modern prostate cancer treatment because of its proven ability to improve progression-free survival and help maintain quality of life in eligible patients.
Unlike conventional chemotherapy, ENZALIEVA 40 MG specifically targets pathways involved in prostate cancer growth, making it a highly effective option for selected patients. It is often prescribed as part of a comprehensive oncology treatment plan under the supervision of experienced healthcare professionals.
Manufactured according to stringent pharmaceutical quality standards, ENZALIEVA 40 MG is designed to deliver consistent therapeutic performance, safety, and reliability.
Regular follow-up appointments, laboratory testing, and clinical evaluations are important during treatment to monitor effectiveness and manage any potential side effects.
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is primarily used for the treatment and management of advanced prostate cancer.
The medicine is commonly used in patients whose cancer continues to progress despite hormone-lowering therapy.
Enzalutamide helps delay disease progression in patients who do not yet have detectable metastases.
The medicine may be prescribed as part of combination treatment plans for metastatic hormone-sensitive disease.
Doctors frequently recommend Enzalutamide to help control advanced-stage prostate cancer.
The medicine may be used when prostate cancer returns after previous treatments.
Enzalutamide plays an important role in targeted hormonal cancer treatment strategies.
The medicine supports ongoing disease control and helps delay cancer progression.
Enzalutamide belongs to a class of medicines known as Androgen Receptor Inhibitors.
ENZALIEVA works by:
This targeted mechanism helps interfere with the hormonal signals that prostate cancer cells need to survive and spread.
Like all medicines, ENZALIEVA 40 MG may cause side effects in some patients. The severity and frequency of side effects vary from person to person.
Tiredness and lack of energy are commonly reported during treatment.
Patients may experience episodes of warmth, sweating, or flushing.
Blood pressure levels may increase during therapy.
Some patients experience discomfort in the muscles or joints.
Headaches may occur during treatment.
Occasional dizziness or lightheadedness may develop.
Changes in appetite may affect food intake.
General weakness may occur in some patients.
Sleep disturbances may occasionally be reported.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if any serious symptoms occur.
The dosage of ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) should always be determined by a qualified oncologist.
The stage and severity of prostate cancer influence treatment planning.
Doctors may adjust treatment based on therapeutic effectiveness.
Existing medical conditions may affect dosage recommendations.
Other medicines may interact with Enzalutamide and require adjustments.
Individual patient characteristics influence treatment decisions.
Before starting treatment, inform your doctor if you have:
Patients should also inform their healthcare provider about all prescription medicines, over-the-counter medications, vitamins, and herbal supplements they are currently taking.
Women who are pregnant or planning pregnancy should avoid exposure to damaged capsules.
It is used for the treatment of advanced prostate cancer, including metastatic and castration-resistant prostate cancer.
Enzalutamide is a targeted hormonal therapy that blocks androgen receptor signaling to help control prostate cancer growth.
No. It is a targeted hormonal therapy and works differently from traditional chemotherapy medicines.
Yes. It is commonly prescribed for patients with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.
Its primary action is blocking androgen receptor activity rather than directly lowering testosterone production.
Yes. Fatigue is one of the most commonly reported side effects during treatment.
Yes. Routine medical evaluations and monitoring are important throughout treatment.
Yes. This medicine should only be used under the guidance of qualified healthcare professionals experienced in oncology and prostate cancer management.